Diede Brunen - Concepedia

Author

Diede Brunen

The Netherlands Cancer Institute

Also Known As

D. Brunen, Diede Brunen

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute University Medical Center Utrecht Oncode Institute University of California, San Francisco Cancer Genomics Centre

About

Diede Brunen is an author at The Netherlands Cancer Institute specializing in medicine, cancer research, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	583
2	Cell Biology	2	2	198
3	Biomolecular Engineering	1	1	49
4	Microbiology	1	1	72
5	Pathology	1	1	126

Diede Brunen

Publications

Citations

H-Index

Page 1

	Year	Citations
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential Liqin Wang, Rodrigo Leite de Oliveira, Sanne C.F.A. Huijberts, Cell Tumor BiologyAcquired VulnerabilityMedicinePhotocarcinogenesisMelanoma	2018	336
TGF-β: An emerging player in drug resistance Diede Brunen, Stefan M. Willems, Udo Kellner, Cell Cycle Tumor BiologyOncologyCancer Drug ResistanceMedicineTgf-β Signaling	2013	126
Rapid Temporal Control of Foxp3 Protein Degradation by Sirtuin-1 Jorg van Loosdregt, Diede Brunen, Veerle Fleskens, PLoS ONE	2011	112
Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data Subarna Sinha, Danièl Thomas, Steven M. Chan, Nature Communications	2017	97
FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma Koos Koole, Diede Brunen, Pauline M.W. van Kempen, Clinical Cancer Research	2016	91
An ATG16L1-dependent pathway promotes plasma membrane repair and limits Listeria monocytogenes cell-to-cell spread Joel M. J. Tan, Nora Mellouk, Suzanne E. Osborne, Nature Microbiology Limits Listeria MonocytogenesVirulence FactorPathogenesisAutophagyAtg16l1-dependent Pathway Promotes	2018	72
Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities Jean‐Philippe Coppé, Miki Mori, Bo Pan, Nature Cell Biology Tumor BiologyPhospho-catalytic DependenciesOncogenic AgentProtein PhosphorylationAnti-cancer Agent	2019	49
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors Ana Ruiz-Sáenz, Chloé E. Atreya, Changjun Wang, Nature Cancer	2023	42
High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates Jens Verheyen, Chris Verhofstede, Elena Knops, AIDS	2010	37
PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma Diede Brunen, Romy C. de Vries, Cor Lieftink, Molecular Cancer Therapeutics	2018	34

Page 1